title: Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma.
abstract: In the present study, we evaluated the ophthalmologic outcomes of 24 patients who received chemotherapy and/or radiotherapy for the treatment of non-conjunctival ocular adnexal mucosa-associated lymphoid tissue-type (MALT) lymphoma. Ophthalmologic outcomes were assessed in patients who received chemotherapy and/or radiotherapy from March 2004 until May 2010. Outcomes were determined according to common symptoms following chemotherapy and/or radiotherapy, which consisted of decreased visual acuity, dry eye symptoms, retinopathy, optic neuropathy, increased intraocular pressure, and blepharitis. Nine patients received chemotherapy alone, eight patients received radiotherapy alone, and seven patients received chemotherapy with additional radiotherapy (chemoradiation therapy). Patients treated by chemotherapy alone showed better ophthalmologic outcome scores (mean score, 1.56) than those treated by radiation alone or chemoradiation therapy (mean score, 4.01). In conclusion, the treatment of ocular adnexal lymphoma including radiotherapy showed poor ophthalmologic outcomes due to radiation-induced complications. Recently, many new treatment options have emerged, such as immunotherapy or radioimmunotherapy. In the future study, to select a better treatment modality with fewer complications, well-designed prospective trials with ophthalmologic outcomes are needed.
authors.affiliation: Department of Ophthalmology and Visual Science, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-ku, Seoul, 137-701, Republic of Korea.
authors.forename: Ji-Sun
authors.initials: JS
authors.lastname: Paik
authors.forename: Won-Kyung
authors.initials: WK
authors.lastname: Cho
authors.forename: Sung-Eun
authors.initials: SE
authors.lastname: Lee
authors.forename: Byung-Ock
authors.initials: BO
authors.lastname: Choi
authors.forename: Seung-Eun
authors.initials: SE
authors.lastname: Jung
authors.forename: Gyeong-Sin
authors.initials: GS
authors.lastname: Park
authors.forename: Sung-Hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Suk-Woo
authors.initials: SW
authors.lastname: Yang
authors.forename: Seok-Goo
authors.initials: SG
authors.lastname: Cho
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001762:Blepharitis / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D002386:Cataract / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005134:Eye Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007766:Lacrimal Apparatus Diseases / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D009901:Optic Nerve Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D009918:Orbital Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012164:Retinal Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014985:Xerophthalmia / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone